According to Piper Jaffray, Vertex Pharmaceuticals VRTX reported full Phase III REALIZE results in HCV interferon-failure patients showing a combined Sustained Virologic Response (SVR) rate of 65% vs. only 17% for standard of care.
Piper Jaffray reported that importantly, Telaprevir achieved an SVR rate of 31% in hardest-to-treat prior null responders, 6x that of control arm at only 5%. “We are buyers of VRTX shares on weakness ahead of the late April AdComm meetings and Telaprevir's May 23rd PDUFA date. We reiterate our Overweight rating and $52 target based on an NPV of projected corporate cash flow through 2021 discounted back at 15%. Telaprevir approval could cause us to reevaluate our 15% discount rate and impact our price target.”
Vertex Pharmaceuticals closed yesterday at $47.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBiotechnologyHealth CarePiper JaffrayTelecommunication Servicesvertex pharmaceuticalsWireless Telecommunication Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in